NO20032773L - Farmasöytisk preparat som omfatter pyrsazolo [4,3-d] pyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner ellerprostaglandinderivater - Google Patents

Farmasöytisk preparat som omfatter pyrsazolo [4,3-d] pyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner ellerprostaglandinderivater

Info

Publication number
NO20032773L
NO20032773L NO20032773A NO20032773A NO20032773L NO 20032773 L NO20032773 L NO 20032773L NO 20032773 A NO20032773 A NO 20032773A NO 20032773 A NO20032773 A NO 20032773A NO 20032773 L NO20032773 L NO 20032773L
Authority
NO
Norway
Prior art keywords
pyrsazolo
antithrombotics
prostaglandins
pyrimidines
pharmaceutical preparation
Prior art date
Application number
NO20032773A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032773D0 (no
Inventor
Hans-Michael Eggenweiler
Volker Eiermann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10063224A external-priority patent/DE10063224A1/de
Priority claimed from DE2000163882 external-priority patent/DE10063882A1/de
Priority claimed from DE2000164993 external-priority patent/DE10064993A1/de
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20032773L publication Critical patent/NO20032773L/no
Publication of NO20032773D0 publication Critical patent/NO20032773D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20032773A 2000-12-19 2003-06-18 Farmasöytisk preparat som omfatter pyrsazolo [4,3-d] pyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner ellerprostaglandinderivater NO20032773D0 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10063224A DE10063224A1 (de) 2000-12-19 2000-12-19 Pharmazeutische Formulierung enthaltend Pyrazolo(4,3-d)pyrimidine und Antithrombotica
DE2000163882 DE10063882A1 (de) 2000-12-21 2000-12-21 Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Calcium-Antagonisten
DE2000164993 DE10064993A1 (de) 2000-12-23 2000-12-23 Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Prostaglandine oder Prostaglandinderivate
PCT/EP2001/013916 WO2002049651A1 (de) 2000-12-19 2001-11-28 Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate

Publications (2)

Publication Number Publication Date
NO20032773L true NO20032773L (no) 2003-06-18
NO20032773D0 NO20032773D0 (no) 2003-06-18

Family

ID=27214208

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032773A NO20032773D0 (no) 2000-12-19 2003-06-18 Farmasöytisk preparat som omfatter pyrsazolo [4,3-d] pyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner ellerprostaglandinderivater

Country Status (16)

Country Link
US (1) US20040063730A1 (es)
EP (1) EP1343506A1 (es)
JP (1) JP2004516270A (es)
KR (1) KR20030059349A (es)
CN (1) CN1481244A (es)
AR (1) AR035676A1 (es)
AU (1) AU2002229573A1 (es)
BR (1) BR0115995A (es)
CA (1) CA2431077A1 (es)
CZ (1) CZ20031776A3 (es)
HU (1) HUP0303315A2 (es)
MX (1) MXPA03005393A (es)
NO (1) NO20032773D0 (es)
PL (1) PL362513A1 (es)
SK (1) SK8192003A3 (es)
WO (1) WO2002049651A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035531A1 (es) * 2001-01-22 2004-06-02 Novartis Ag Composicion para el control de plagas endoparasiticas en ganados y animales domesticos, un metodo para su control y el uso de dicha composicion para la preparacion de medicamentos
EP1348707B1 (en) * 2002-03-28 2010-08-25 Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
RS20050810A (en) 2003-04-29 2007-08-03 Pfizer Inc., 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
WO2004110354A2 (en) * 2003-05-15 2004-12-23 Roskamp Research, Llc Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
ES2317209T3 (es) * 2004-04-07 2009-04-16 Pfizer Inc. Pirazolo(4,3-) pirimidinas.
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
WO2009046323A1 (en) * 2007-10-05 2009-04-09 Roskamp Research Llc Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
NZ591601A (en) * 2008-08-13 2012-12-21 Actelion Pharmaceuticals Ltd Therapeutic compositions containing macitentan and a prostacyclin receptor agonist
US20180015090A1 (en) * 2015-01-28 2018-01-18 Realinn Life Science Limited COMPOUNDS FOR ENHANCING PPARy EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
KR102507967B1 (ko) 2016-09-09 2023-03-09 인사이트 코포레이션 Hpk1 조절제로서의 피라졸로피리딘 유도체 및 암을 치료하기 위한 이의 용도
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3612030A4 (en) 2017-04-21 2021-04-28 Ikena Oncology, Inc. AHR INDOLE INHIBITORS AND THEIR USES
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
IL276779B2 (en) 2018-02-20 2024-04-01 Incyte Corp Derivatives and related compounds of N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide as HPK1 inhibitors for cancer treatment
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
PE20221419A1 (es) 2019-08-06 2022-09-20 Incyte Corp Formas solidas de un inhibidor de hpk1
JP2023502531A (ja) 2019-11-26 2023-01-24 イケナ オンコロジー， インコーポレイテッド 多形カルバゾール誘導体およびその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2353285A1 (fr) * 1975-09-17 1977-12-30 Doms Laboratoires Medicament vasodilatateur coronarien perfectionne
JPS5459266A (en) * 1977-10-14 1979-05-12 Ono Pharmaceut Co Ltd Prostaglandin i2 analogs and their preparation
FR2568774B2 (fr) * 1984-05-30 1989-05-19 Choay Sa Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique
FR2672601B1 (fr) * 1991-02-08 1994-10-14 Synthelabo Derives de benzo-1,5-thiazepine, leur preparation et leur application en therapeutique.
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
DE19709877A1 (de) * 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
WO1999021558A2 (en) * 1997-10-28 1999-05-06 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
DE19942474A1 (de) * 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
DE10058662A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
DE10103647A1 (de) * 2001-01-27 2002-08-01 Merck Patent Gmbh Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates

Also Published As

Publication number Publication date
AR035676A1 (es) 2004-06-23
CZ20031776A3 (cs) 2003-09-17
NO20032773D0 (no) 2003-06-18
EP1343506A1 (de) 2003-09-17
AU2002229573A1 (en) 2002-07-01
KR20030059349A (ko) 2003-07-07
SK8192003A3 (en) 2003-10-07
BR0115995A (pt) 2004-01-13
CA2431077A1 (en) 2002-06-27
WO2002049651A1 (de) 2002-06-27
MXPA03005393A (es) 2003-09-25
JP2004516270A (ja) 2004-06-03
US20040063730A1 (en) 2004-04-01
PL362513A1 (en) 2004-11-02
HUP0303315A2 (hu) 2004-01-28
CN1481244A (zh) 2004-03-10

Similar Documents

Publication Publication Date Title
NO20032773D0 (no) Farmasöytisk preparat som omfatter pyrsazolo [4,3-d] pyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner ellerprostaglandinderivater
EE05376B1 (et) Vesisuspensioonip?hineÁparenteraalneÁravimpreparaatÁjaÁsedaÁsisaldavÁviaal
DK1349839T3 (da) Phenylethenyl- eller phenylethinylderivater som glutamatraceptorantagonister
DK1416935T3 (da) 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
NO20030418D0 (no) Nytt farmasöytisk preparat
DK1224175T3 (da) Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
NO20043064L (no) 1-alkyl-1-azoniabisyklo [2.2.2] oktankarbamatderivater og anvendelse av disse som muskarine reseptorantagonister
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
DK1379511T3 (da) Dihydro-benzo[b][1,4]diazepin-2-on-derivater som mGLuR2-antagonister II
IS6443A (is) Pýridó[2,3-d]pýrimidín-2,7-díamín kínasa latar
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
NO20005399L (no) Farmasöytisk preparat
NO20032142L (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
NO20020574L (no) Substituerte 1,5-dihydropyrrol-2-on derivater som er virksomme som NMDA-reseptorantagonister for behandlingen avsmertetilstanden
NO20015149L (no) Nytt farmasöytisk preparat
IS6821A (is) Samrunnar afleiður púríns sem mótlyf A1-adenósínviðtakans
ATE309220T1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate
NO20032772L (no) Farmasöytisk preparat som omfatter tienopyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner eller prostaglandinderivater
NO20015148D0 (no) Nytt farmasöytisk preparat
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
DK1347974T3 (da) Aminotriazolopyridinderivater som adenosinreceptorligander
IT1320016B1 (it) Procedimento per la fabbricazione di strutture di giunzione a saccheprofonde.
NO20015104D0 (no) Nytt farmasöytisk preparat
NO20015105D0 (no) Nytt farmasöytisk preparat